Press Releases
GNS Appoints John Maraganore, PhD, as Strategic Advisor
GNS today announced that John Maraganore, PhD, biopharma industry leader and the former founding CEO of Alnylam Pharmaceuticals, has joined GNS as a strategic advisor.
GNS and the Global Alzheimer’s Platform Foundation® Partner to advance Alzheimer’s R&D
3-year partnership will leverage biomarker database and AI for innovation to create“Digital Twins” that help uncover the complex biology driving Alzheimer’s Disease
GNS Healthcare and Arvinas Enter into Neuroscience Drug Discovery Collaboration
GNS Healthcare, today announced a collaboration with Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, to generate insights to help accelerate drug development for neurodegenerative diseases…
GNS Healthcare Hires Industry Veteran, Joseph F. Donahue, as Chief Business Officer
GNS Healthcare, the leader in the use of “Virtual Patients”, Causal AI and simulation technology for biopharmaceutical companies, today announced the hiring of Joseph F. Donahue as Chief Business Officer…
GNS Healthcare and Scipher Medicine® Collaborate to Develop World’s First in silico Patient for Rheumatoid Arthritis
- Partnership leverages Scipher Medicine’s proprietary patient clinico-genomic data - In silico patient models enable pharmaceutical companies to understand what disease treatments work for which patients and why Somerville, Mass., and Waltham, Mass. ...
GNS Healthcare Announces a Multi-Year Collaboration with a Leading US Cancer Center to Advance Precision Medicine in Oncology
Collaboration with Memorial Sloan Kettering Cancer Center’s Innovation Hub aims to answer key questions in prostate cancer patient care and accelerate discovery and development of new treatments Somerville, Mass.– October 5, 2021– GNS Healthcare (GNS), an artificial...
GNS to Develop the World’s First in silico Patient For Prostate Cancer
Somerville, Mass., May 25, 2021: GNS Healthcare, an artificial intelligence company creating in silico patients that simulate drug treatment at the individual patient level, today announced plans to develop and launch Gemini — The in silico Patient™ for Prostate...
GNS to Develop the World’s First in silico Patient For Prostate Cancer
Somerville, Mass., May 25, 2021: GNS Healthcare, an artificial intelligence company creating in silico patients that simulate drug treatment at the individual patient level, today announced plans to develop and launch Gemini — The in silico Patient™ for Prostate...
GNS Healthcare Hires Alan Kilyk as Chief Financial Officer
Somerville, MA: GNS Healthcare, an AI company creating in silico patients to simulate disease progression and drug treatment at the individual patient level, is pleased to announce that accomplished finance executive Alan Kilyk has joined the company’s leadership team...
QIAGEN Adopts GNS Healthcare’s Gemini – The in silico Patient™ Across Multiple Cancers
Partnership enables enhanced capability to discover new targets and prognostic markers Somerville, MA: GNS Healthcare, the leading AI-driven precision medicine company, today announced a partnership with QIAGEN, the leading global provider of Sample to Insight...